Abstract
Background: CD19-specific chimeric antigen receptor (CAR)-modified T cells infusion is a promising therapy for patients with relapsed/refractory CD19+ B cell malignancies. Early in our institution's CAR-T program, 2 anecdotal cases of B-ALL patients developed AML post CAR-T with karyotypic aberrations noted prior to infusion.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
